Announcements
- OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
- OpGen Announces Acquisition of Preferred Stock by David Lazar
- OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
- OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
- OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
- OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
- OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
- OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
- OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 1.34m |
Free float | 1.28m |
P/E (TTM) | -- |
Market cap | 3.36m USD |
EPS (TTM) | -40.91 USD |
Data delayed at least 15 minutes, as of May 20 2024 07:32 BST.
More ▼